Request a representative visit or G7 15 Day or G7 samples
The CONNECT Clinical Trial
Summary
Summary of multiple studies examining CGM among adults with type 2 diabetes receiving noninsulin or basal insulin therapy across clinical and real-world settings.
Background
The CONNECT Trial was the first multicenter, randomized controlled trial to evaluate Dexcom CGM as the primary intervention in adults with type 2 diabetes not using insulin. Conducted across more than 22 primary care practices in the U.S., the study assessed the impact of CGM on glycemic outcomes over 26 weeks while participants continued their existing diabetes therapies.
Main outcomes
- Participants using Dexcom CGM achieved significantly greater A1C reductions than the control group, with an overall A1C decrease of 1.6% from a baseline of 8.8%. Among those with baseline A1C ≥10%, A1C decreased by 3.1%.
- More than two-thirds of CGM users achieved an A1C below 7.5%, and nearly half achieved an A1C below 7.0% after 26 weeks.
- Time in Range doubled from 31% to 62% in the CGM group, representing an average increase of approximately five hours per day. Patients also reported greater satisfaction and reduced diabetes-related burden compared with SMBG.
What this means for your practice
- CGM can help patients with type 2 diabetes not using insulin achieve meaningful improvements in glycemic outcomes while continuing their existing treatment plans.
- Real-time glucose insights may support greater patient engagement and provide opportunities for more informed diabetes management discussions.
- Improvements in both A1C and Time in Range demonstrate the value of CGM in helping patients better understand and manage their glucose levels in primary care settings.
References
- Martens, T. Presented at American Diabetes Association 2026 Scientific Sessions, June 6, 2026; New Orleans, LA; USA.
- Reed J, Dong T, Eaton E, et al. Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial. Diabetes Obes Metab. 2024;26(7):2881-2889. doi:10.1111/dom.15608
- Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400-405. doi:10.2337/dc18-1444
- Shah VN, Kanapka LG, Akturk HK, et al. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study. Diabetes Technol Ther. 2024;26(4):246-251. doi:10.1089/dia.2023.0486
- Kovatchev BP, Lobo B, Fabris C, et al. The Virtual DCCT: Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications. Diabetes Technol Ther. 2025;27(3):209-216. doi:10.1089/dia.2024.0404
For a deeper dive on this topic, visit GlucoseTech
